CVRx (NASDAQ:CVRX) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of CVRx (NASDAQ:CVRX) from a hold rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

Several other equities research analysts have also recently commented on CVRX. William Blair cut CVRx from an “outperform” rating to a “market perform” rating in a research report on Friday. Cantor Fitzgerald decreased their target price on CVRx from $13.00 to $5.00 and set an “overweight” rating for the company in a research report on Monday, August 17th. Piper Sandler cut shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research note on Friday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Friday, October 30th. Finally, Canaccord Genuity Group downgraded shares of CVRx from a “buy” rating to a “hold” rating and dropped their price target for the company from $5.00 to $2.00 in a report on Friday. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CVRx has an average rating of “Hold” and a consensus price target of $3.70.

CVRx Price Performance

Shares of NASDAQ CVRX opened at $0.87 on Friday. CVRx has a twelve month low of $0.77 and a twelve month high of $10.28. The firm has a market cap of $23.14 million, a P/E ratio of -0.43 and a beta of 0.81. The company has a 50 day moving average of $2.08 and a 200 day moving average of $5.16. The company has a quick ratio of 6.87, a current ratio of 8.04 and a debt-to-equity ratio of 2.94.

CVRx (NASDAQ:CVRX) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.02). The business had revenue of $13.83 million during the quarter, compared to the consensus estimate of $13.93 million. CVRx had a negative net margin of 88.28% and a negative return on equity of 180.78%. As a group, research analysts expect that CVRx will post -2.00 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Brent Binkowski purchased 26,223 shares of the stock in a transaction dated Thursday, August 13th. The shares were purchased at an average cost of $2.91 per share, with a total value of $76,308.93. Following the acquisition, the chief operating officer directly owned 56,514 shares of the company’s stock, valued at $164,455.74. This represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 16.60% of the company’s stock.

Institutional Trading of CVRx

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its position in CVRx by 2,137.6% in the third quarter. Russell Investments Group Ltd. now owns 100,937 shares of the company’s stock worth $177,000 after purchasing an additional 96,426 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in shares of CVRx during the 3rd quarter valued at about $87,000. Bank of America Corp DE bought a new stake in shares of CVRx during the 2nd quarter valued at about $102,000. BlackRock Inc. purchased a new stake in shares of CVRx during the 2nd quarter valued at about $6,402,000. Finally, Deutsche Bank AG purchased a new stake in shares of CVRx during the 2nd quarter valued at about $62,000. Institutional investors own 75.27% of the company’s stock.

Key Headlines Impacting CVRx

Here are the key news stories impacting CVRx this week:

• Neutral Sentiment: Trading in CVRx was temporarily paused under a Limit Up-Limit Down (LULD) volatility mechanism. The halt signals unusually volatile trading but does not, by itself, explain the move. Trading halt notice
• Negative Sentiment: CVRx reported Q3 revenue of $13.83 million, below the roughly $13.93 million analyst expectation, and a loss of $0.52 per share versus estimates of about $0.50. Revenue declined year over year, and the company lowered its FY2026 outlook, raising concerns about growth and execution. CVRx reports Q3 revenue decline and lowers outlook
• Negative Sentiment: Canaccord Genuity cut its rating from Buy to Hold and reduced its price target from $5 to $2. William Blair also downgraded the stock, moving from Outperform to Market Perform. The lowered ratings and targets add pressure despite the $2 target remaining above the recent share price. William Blair downgrade

CVRx Company Profile

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.